U.S. stock futures flat as earnings pour in; Fed decision looms


By Arjun Panchadar

Oct 30 (Reuters) - U.S. stock index futures were little changed on Wednesday as investors digested a fresh batch of earnings reports ahead of a widely expected interest rate cut by the Federal Reserve later in the day.

The central bank has already lowered borrowing costs twice this year, with a drawn out U.S.-China trade war taking a toll on the domestic economy and raising fears of a slowdown.

Odds of a rate cut have ballooned to over 97% from about 40% a month earlier. Hopes of a rate cut and optimism around trade talks have pushed the benchmark S&P 500 to record highs in the last two sessions.

Nearly half of the S&P 500 companies have posted quarterly results so far, of which 77.1% have beaten profit estimates. Still, analysts are expecting a 1.9% drop in third-quarter earnings, according to Refinitiv data.

General Electric Co GE.N gained 5.2% in premarket trading after the industrial conglomerate beat quarterly profit estimates and raised its cash forecast for the year.

Advanced Micro Devices Inc AMD.O dropped 1.3% after the chipmaker forecast fourth-quarter sales below expectations.

Before the Fed's policy decision, a Commerce Department's gross domestic product report is likely to indicate that the U.S. economy is losing speed, but not tipping into recession.

The data, due at 8:30 a.m. ET, is likely to show U.S. economy slowed to 1.6% in the third quarter from 2% in the April-June period.

At 7:15 a.m. ET, Dow e-minis 1YMcv1 remained unchanged. S&P 500 e-minis EScv1 were up 0.75 points, or 0.02% and Nasdaq 100 e-minis NQcv1 were up 7.75 points, or 0.1%.

Among other stocks, Mattel Inc MAT.O surged nearly 20% after the toymaker reported a surprise jump in quarterly revenue on higher demand for newer models of its flagship Barbie brand and dolls based on Korean pop-sensation BTS.

Johnson & Johnson JNJ.N rose 2.8% as the company said 15 new tests found no asbestos in a bottle of baby powder that the U.S. Food and Drug Administration says tested positive for trace amounts of asbestos. FDA said it stands by its finding.

(Reporting by Arjun Panchadar in Bengaluru)

((Arjun.Panchadar@thomsonreuters.com; within U.S. +1-646-223-8780; outside U.S. +918067492767;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.